Investment Summary

GIMV and EQT Life Sciences Invest In iSTAR Medical

On September 5, 2019, private equity firm GIMV and growth capital firm EQT Life Sciences invested in medical products company iSTAR Medical

Investment Highlights
  • This is GIMV’s 8th and EQT Life Sciences’ 11th transaction in the Medical Products sector.
  • This is GIMV’s 41st and EQT Life Sciences’ 4th transaction in Belgium.

Investment Summary

Date 2019-09-05
Target iSTAR Medical
Sector Medical Products
Investor(s) GIMV
EQT Life Sciences
Deal Type Venture

Target

iSTAR Medical

Wavre, Belgium
iSTAR Medical is a private medical device company developing novel ophthalmic implants for the treatment of glaucoma. iSTAR Medical was founded in 2010 and is based in Wavre, Belgium.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 2

Investor

GIMV

Antwerp, Belgium

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1980
PE ASSETS 2.0B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.


DEAL STATS #
Overall 132 of 170
Sector: Medical Products M&A 8 of 8
Type: Venture M&A Deals 35 of 39
Country: Belgium M&A 41 of 50
Year: 2019 M&A 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-30 thinkstep AG

Leinfelden-Echterdingen, Germany

thinkstep AG is a provider of software and consulting services supporting companies globally in sustainability management and reducing their environmental footprint. In the last few years, thinkstep has continuously expanded its impressive customer base and now serves over 2,000 clients in 20 industries, including a large number of Fortune 500 companies in Germany and around the world.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-01 Rehaneo

Munich, Germany

Rehaneo is a provider of ambulatory rehab, aftercare, prevention and occupational health management across Germany. The company aims to provide patients with access to the highest quality ambulatory care and support their way to a fast and sustainable recovery. Rehaneo was founded in 2020 and is based in Munich, Germany.

Buy -
Investor

EQT Life Sciences


Category Growth Capital Firm
Founded 1987
PE ASSETS 3.5B EUR
Size Large
Type Sector Focused
DESCRIPTION

EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid?stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.


DEAL STATS #
Overall 25 of 47
Sector: Medical Products M&A 11 of 14
Type: Venture M&A Deals 21 of 39
Country: Belgium M&A 4 of 5
Year: 2019 M&A 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-18 Imcyse

Angleur, Belgium

Imcyse is a developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases. Imcyse was founded in 2010 and is based in Angleur, Belgium.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-04-22 FoRx Therapeutics

Basel, Switzerland

FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways. FoRx Therapeutics was founded in 2019 and is based in Basel, Switzerland.

Buy -